The present invention relates to the field of noninvasive oxygen delivery measurement using optical based sensors, and in particular, to displaying indication(s) of a patient's oxygen state.
The measurement of oxygen delivery to the body and the corresponding oxygen consumption by the body's organs and tissues is vitally important to medical practitioners in the diagnosis and treatment of various medical conditions. Oxygen delivery is useful, for example, during certain medical procedures, where artificially providing additional oxygen to the patient's blood stream may become necessary. Patients may need supplemental oxygen in surgery, conscious sedation, or the intensive care unit. For example, during an intubation procedure, the patient will stop breathing while the procedure is performed. The patient is typically provided with oxygen before the intubation procedure. However, because the patient stops breathing during an intubation procedure, the patient's blood oxygen saturation level can fall. The medical practitioner must ensure that the patient has sufficient reserves of oxygen in the system before intubation so that suffocation is avoided during the intubation procedure. At the same time, providing oxygen at a high pressure to a patient can have its own negative effects in some patients, some of which include damages to the patient's lungs, and in particular, to the alveoli structures in the lungs. In some patients, for example neonates, even oxygen levels on the high end of a normal oxygenation range can cause blindness.
When oxygen molecules come into contact with blood, the majority of the oxygen molecules are bound to the hemoglobin in red-blood cells and a small portion is dissolved directly in the blood plasma. The current standard of care is to measure oxygen delivery through the use of a pulse oximeter. Pulse oximeters noninvasively measure and display oxygen saturation (SpO2), which is the percentage of the patient's hemoglobin bound to oxygen molecules.
Another possible indicator of oxygen delivery is the partial pressure of oxygen (PaO2) in the arterial blood. However, there are currently no reliable ways to measure arterial PaO2 noninvasively. Invasive PaO2 measurements require a blood gas analysis. The analysis may be needed intermittently during a surgical procedure and can interrupt and/or delay the surgical procedure. The analysis may require expensive sensors. Invasive PaO2 measurements may also carry serious side effects that can harm the health of a patient.
One of the challenges of commercially available physiological monitors that provide SpO2 readings is that the relationship between a patient's PaO2 and SpO2 is not linear. Specifically, SpO2 measured by pulse oximetry can be reported as high as about 98% even when PaO2 is as low as about 70 mmHg. A patient can be in a hypoxic state when the patient's PaO2 falls below about 80 mmHg. Therefore, SpO2 may not provide advance warning of falling arterial oxygenation until the patient's PaO2 is already in the hypoxia range, which may not be adequate for providing advance warning of impending hypoxia. In an effort to prevent hypoxia, clinicians can provide supplemental oxygen to maintain SpO2 at greater than about 98% during surgery to provide a “safety cushion” of oxygenation in the event of unexpected changes in oxygen delivery. However, the “safety cushion” can result in significant hyperoxia. When the SpO2 level reaches or is close to 100%, the PaO2 level can continue to rise if oxygen continues to be dissolved in the plasma. SpO2 is not able to inform clinicians or any other users of an increasing amount of oxygen dissolved in the patient's blood beyond 100% SpO2, when substantially all the hemoglobin has been fully saturated with oxygen modules. Hyperoxia have its own negative effects, including those described above. Therefore, providing information of the patient's hypersaturation condition can be helpful in allowing the clinician to stop delivery of supplemental oxygen temporarily and resume oxygen delivery when it is safe to do so.
Pulse oximeters according to the present disclosure can provide an index indicative of oxygen dissolved in the blood (hereinafter referred to as the “dissolved oxygen index” or the “index”). Example methods of determining such an index are described in U.S. Pat. No. 9,131,881, titled “ ”HYPERSATURATION INDEX” and issued Sep. 15, 2015, the entirety of which is incorporated by reference herein. An example of the index is the Oxygen Reserve Index™ (ORi™). The index can add to or supplement information from SpO2, and/or invasive PaO2 measurements using other equipment. The index is configured to provide information about oxygen dissolved in a patient's blood, which can indicate the patient's oxygenation in a moderate hyperoxic range. The moderate hyperoxic range can be, for example, when the patient's PaO2 is between about 100 mmHg to about 200 mmHg. The pulse oximeter can be a standalone device or docked to a multi-parameter medical hub. The index can be displayed on a display screen of the standalone device and/or on a display screen of the medical hub.
The present disclosure provides various displays of indications of a patient's oxygen state including a patient's blood oxygenation state, such as the index, a patient's impending hypoxia and/or hyperoxia, and/or SpO2. For example, the displays can inform a user of the patient's index when SpO2 is high, such as greater than about 98%. Displaying various oxygen state indications on the same screen can provide a more comprehensive picture of the patient's oxygen state than displaying only SpO2. The displays can be useful for patients who are on supplemental oxygen therapy, a ventilator or closed-loop positive pressure delivery device, or for any other medical applications where a patient's oxygen state needs to be monitored.
Another one of the challenges of commercially available physiological monitors is the limited display screen size, when patient monitors continue to expand in the number and type of monitored parameters made available to a user for review. Although a user is able to conveniently access a large amount of a patient's data from a single display screen, the display can become cluttered with the large number of parameters. It can also be challenging for the user to quickly and accurately understand the various oxygen state parameters shown on the display screen, among other physiological parameters, so as to make decisions about how to care for the patient.
The displays of oxygen state indications according to the present disclosure can be compact, and/or able to provide direct visual information of various aspects of the patient's oxygen state to a user reading the display screen. Examples of the aspects of the patient's oxygen state can include graphs, symbols, numerical indications, and/or a combination thereof, of SpO2, the index, such as ORi™, and/or an increasing or decreasing trend of the index.
A noninvasive patient monitoring system for providing an indication of a patient's oxygen state system for providing an indication of a patient's oxygen state can comprise one or more sensors for outputting signals in response to a plurality of a patient's physiological parameters; one or more signal processors configured to receive the signals and calculate a first indicator responsive to a percentage of hemoglobin molecules bound to oxygen, a second indicator responsive to a quantity of oxygen dissolved in the patient's blood and not bound to any hemoglobin molecule, the second indicator providing different information to a caregiver than the first indicator, and a third indicator responsive to an increasing or decreasing trend of the second indicator; and a display responsive to output of the one or more signal processors to display the first, second, and third indicators. The first indicator can comprise the patient's oxygen saturation. The first indicator can be displayed as a graph and/or a numerical value. The second indicator can comprise a noninvasive index of dissolved oxygen in blood of the patient. The second indicator can be displayed as a plurality of shapes, the number of shapes being displayed corresponding to the patient's noninvasive index of dissolved oxygen in the blood. The shape can be a rectangle, a circle, a triangle, or a diamond. No shape may be displayed when the first indicator is below about 98%. The third indicator can further comprise a rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The third indicator can be displayed as an arrow pointing at an angle, a direction of the arrow corresponding to the increasing or decreasing trend of the patient's noninvasive index of dissolved oxygen in the blood and a magnitude of the angle corresponding to the rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The arrow can be displayed as pointing generally horizontally when the first indicator is below about 98%. The second indicator can be displayed as a shape that is empty, partially filled, or fully filled, the amount of filling corresponding to the patient's noninvasive index of dissolved oxygen in the blood. The shape can be empty when the first indicator is below about 98%. The shape can comprise a circle, a triangle, a rectangle, or a diamond. The third indicator can be displayed as a pointer placed at an angle, the pointer coupled with the shape to form a dial, a clock direction of the pointer corresponding to the increasing or decreasing trend of the patient's noninvasive index of dissolved oxygen in the blood and/or the rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The dial can display about 3 o'clock when the first indicator is below about 98%. The one or more sensors can comprise an optical sensor having at least one light emitter emitting light of a plurality of wavelengths into the body of the patient and a light detector detecting the light after attenuation of the body, wherein the attenuation can be responsive to oxygenation of the patient's blood. The first indicator can be determined based at least in part on the detected light. The second indicator can be determined based at least in part on the detected light. The third indicator can be determined based at least in part on the detected light.
A noninvasive patient monitoring system for providing an indication of a patient's oxygen state system for providing an indication of a patient's oxygen state can comprise at least one light emitter emitting light of a plurality of wavelengths into the body of the patient; a light detector detecting the light after attenuation of the body, wherein the attenuation can be responsive to oxygenation of the patient's blood, and outputting one or more signals from the light detector, the one or more signals responsive to said attenuation; one or more signal processors configured to process the one or more signals to electronically calculate a first indicator responsive to a quantity of oxygen dissolved in the patient's blood and not bound to any hemoglobin molecule, and a second indicator responsive to an increasing or decreasing trend of the first indicator; and a display responsive to output of the one or more signal processors to display the first and second indicators. The one or more signal processors can be further configured to calculate a third indicator responsive to a percentage of hemoglobin molecules bound to oxygen, the third indicator providing different information to a caregiver than the first or second indicator, and the display can be configured to display the third indicator. The third indicator can comprise the patient's oxygen saturation. The third indicator can be displayed as a graph and/or a numerical value. The first indicator can comprise the patient's noninvasive index of dissolved oxygen in the blood. The first indicator can be displayed as a plurality of shapes, the number of shapes being displayed corresponding to the patient's noninvasive index of dissolved oxygen in the blood. The shape can be a rectangle, a circle, a triangle, or a diamond. No shape may be displayed when the patient's oxygen saturation is below about 98%. The second indicator can further comprise a rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The second indicator can be displayed as an arrow at an angle, a direction of the arrow corresponding to the increasing or decreasing trend of the patient's noninvasive index of dissolved oxygen in the blood and a magnitude of the angle corresponding to the rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The arrow can be displayed as pointing generally horizontally when the first indicator is below about 98%. The first indicator can be displayed as a shape that is empty, partially filled, or fully filled, the amount of filling corresponding to the patient's noninvasive index of dissolved oxygen in the blood. The shape can be empty when the patient's oxygen saturation is below about 98%. The shape can comprise a circle, a triangle, a rectangle, or a diamond. The second indicator can be displayed as a pointer directed at an angle, the pointer coupled with the shape to form a dial, a clock direction of the pointer corresponding to an increasing or decreasing trend of the patient's noninvasive index of dissolved oxygen in the blood and/or the rate of increase or decrease of the patient's noninvasive index of dissolved oxygen in the blood. The dial can display about three o'clock when the first indicator is below about 98%.
A noninvasive patient monitoring system for providing an indication of a physiological parameter can comprise one or more sensors for outputting signals in response to a patient's physiological conditions; one or more signal processors configured to receive the signals and calculate a first indicator responsive to a magnitude of a physiological parameter, and a second indicator responsive to an increase or decrease of the physiological parameter; and a display responsive to output of the one or more signal processors to display the first and second indications. The second indicator can be further responsive to a rate of change of the physiological parameter. The first indicator can comprise a plurality of shapes, the number of shapes displayed corresponding to the magnitude of the physiological parameter. No shape may be displayed when the physiological parameter is zero or cannot be calculated. The shape can comprise a rectangle, a circle, a triangle, or a diamond. The second indicator can comprises an arrow. An angle of the arrow can correspond to the rate of change of the physiological parameter. The first indicator can comprise a shape that is empty, partially filled, or fully filled, the amount of filling corresponding to the magnitude of the physiological parameter. The shape can be empty when the physiological parameter is zero or cannot be calculated. The shape can comprise a circle, a triangle, a rectangle, or a diamond. The second indicator can comprise a pointer, the pointer coupled with the shape to form a dial, a clock direction of the pointer corresponding to the increase or decrease of the physiological parameter and/or the rate of change of the physiological parameter. The physiological parameter can be a patient's noninvasive index of dissolved oxygen in blood.
A noninvasive patient monitoring system for providing an indication of a patient's oxygen state system for providing an indication of a patient's oxygen state can comprise at least one light emitter emitting light of a plurality of wavelengths into the body of the patient, a light detector detecting the light after attenuation of the body, wherein the attenuation is responsive to oxygenation of the patient's blood, and outputting one or more signals from the light detector, the one or more signals responsive to said attenuation, and one or more signal processors configured to process the one or more signals to electronically calculate an indicator responsive to a quantity of oxygen dissolved in the patient's blood and not bound to any hemoglobin molecule and output an alert of the first indicator plateauing at a maximum value in response to an increase in oxygen supply to the patient. The system can further comprise a display screen responsive to output of the one or more signal processors to display the first indicator. The display can be further configured to display the alert. The system can also be configured to output the alert in an audio form. The first indicator can comprise a plurality of shapes, the number of shapes displayed corresponding to the magnitude of the quantity of oxygen dissolved in the patient's blood and not bound to any hemoglobin molecule. The first indicator can further comprise an indication of an increasing or decreasing trend of the magnitude. The increase in oxygen supply to the patient can be determined by monitoring the patient's FiO2.
The drawings and following associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims. Corresponding numerals indicate corresponding parts, and the leading digit of each numbered item indicates the first figure in which an item is found.
Aspects of the disclosure will now be set forth in detail with respect to the figures and various embodiments. One of skill in the art will appreciate, however, that other embodiments and configurations of the devices and methods disclosed herein will still fall within the scope of this disclosure even if not described in the same detail as some other embodiments. Aspects of various embodiments discussed do not limit the scope of the disclosure herein, which is instead defined by the claims following this description.
The patient monitor 102 can include a display 108, control button(s) 110, and a speaker 112 for audible alerts. The display 108 can include a graphic user-interface, which can be capable of displaying readings of various monitored patient parameters. The readings can include numerical readouts, graphical readouts, animations, and/or the like. The display 108 can include a liquid crystal display (LCD), a cathode ray tube (CRT), a plasma screen, a Light Emitting Diode (LED) screen, Organic Light Emitting Diode (OLED) screen, or any other suitable display.
The host instrument can include one or more displays 208, a keypad 210, a speaker 212 for audio messages, and a wireless signal broadcaster 234. The keypad 210 can comprise a full keyboard, a track wheel, control buttons, and the like. The patient monitor 202 can also include buttons, switches, toggles, check boxes, and the like implemented in software and actuated by a mouse, trackball, touch screen, joystick, or other input device.
The sensor interface 224 can receive the signals from the sensor detector(s) 220 and pass the signals to the processor(s) 226 for processing into representations of physiological parameters. The representations of physiological parameters can be passed to the instrument manager 228. The instrument manager 228 can further process the parameters for display by the host instrument 223. The processor(s) 226 can also communicate with a memory 230 located on the sensor 106. The memory 230 can contain information related to properties of the sensor 106 that can be used during processing of the signals. A non-limiting example of information stored in the memory 230 can be the wavelengths emitted by the emitter 216. The various elements of the processing board 222 described above can provide processing of the detected signals. Tracking medical signals can be difficult because the signals may include various anomalies that do not reflect an actual changing patient parameter. The processing board 222 can apply filters and/or algorithms to detect truly changing conditions from limited duration anomalies. The host instrument 223 can display one or more physiological parameters according to instructions from the instrument manager 228. Additionally, the physiological parameter measurements can be sent to a remote server (such as a cloud server) or to a remote monitoring device, such as a cell phone, tablet, or laptop. The patient monitoring system can include a data transmitter, such as a wireless transmitter or transceiver, for electrically communicating with the remote server or remote monitoring device.
The display 304 can occupy a portion of a front face of the housing 308, or comprise a tablet or tabletop horizontal configuration, a laptop-like configuration or the like. Display information and data can optionally be communicated to a table computer, smartphone, television, or any other display system. The hub 300 can receive data from a patient monitor while docked or undocked from the hub.
Examples of patient monitors that can be docked to the hub 300 can include oximeters or co-oximeters, which are can provide measurement data for a large number of physiological parameters derived from signals output from optical and/or acoustic sensors, electrodes, and/or the like. The physiological parameters can include oxygen saturation, a dissolved oxygen index (such as, for example, ORi™), carboxy hemoglobin, methemoglobin, total hemoglobin, glucose, pH, bilirubin, fractional saturation, pulse rate, respiration rate, components of a respiration cycle, indications of perfusion including perfusion index, signal quality and/or confidences, plethysmograph data, indications of wellness or wellness indexes or other combinations of measurement data, audio information responsive to respiration, ailment identification or diagnosis, blood pressure, patient and/or measurement site temperature, depth of sedation, organ or brain oxygenation, hydration, measurements responsive to metabolism, or combinations of thereof. The hub 300 can also optionally output data sufficient to accomplish closed-loop drug administration in combination with infusion pumps or the like. Additional details of the medical hub 300 are described in U.S. application Ser. No. 14/512,237, filed Oct. 10, 2014 and titled “SYSTEM FOR DISPLAYING MEDICAL MONITORING DATA,” the entirety of which is incorporated herein by reference and should be considered a part of the specification.
As shown in
As described above, clinicians can deliver oxygen to maintain the patient's SpO2 at greater than about 98% during surgery to have some reserve of oxygen in the blood in the event of unexpected changes in oxygen delivery. Such changes can occur due to, for example, cardiac depression, rapid hemorrhage, and/or interrupted ventilation. However, too much excess oxygen above about 98% SpO2 can result in significant hyperoxia, which cannot be known from SpO2 readings.
The patient monitoring system can be configured to measure the patient's hypersaturation conditions, that is, when the patient is in hyperoxia, in addition to monitoring SpO2 and/or invasive PaO2 measurements. The patient monitoring system can also be configured to inform a user of the patient's impending hypoxia. The patient monitoring system can be the patient monitor 102, 202 of
As an example, the hypersaturation conditions can be monitored using pulse oximetry according to the present disclosure. Specifically, pulse oximetry can be used to determine a dissolved oxygen index in addition to SpO2. The index is a dimensionless and continuous parameter configured to provide information about a patient's reserve of oxygen dissolved in the blood stream. This index can provide an indication of the patient's oxygenation in the moderate hyperoxic range. The index can assist a user, such as a medical practitioner in exercising her judgment in ensuring that the patient's blood is not overly hypersaturated with oxygen.
The index can be determined because the balance between oxygen supply and demand can alter venous oxygen saturation. As oxygen supply rises, venous oxygen saturation also increases if the patient's oxygen consumption is stable. During situations in which the SpO2 level is at substantially 100%, the patient's oxygen consumption is stable if hemoglobin count and cardiac output are stable. The patient's oxygen consumption is substantially stable during anesthesia, surgery and some other procedures where the patient's oxygen state needs to be monitored. Change in venous oxygen saturation can result in changes in background light absorption at the plurality of wavelengths emitted by an optical sensor of a pulse oximeter in the presence of hyperoxia. Examples of the plurality of emitted wavelengths can include red and infrared wavelengths. The ratios of light absorption at the plurality of emitted wavelengths can be mapped at varying degrees of hyperoxia to allow calculation of the index based on SvO2, which is the patient's oxygen saturation in the venous blood. Changes in SvO2 can be observed when the patient is in moderate hyperoxia as defined herein and can be used to determine the index.
As shown in
The plurality of bars 508 can be stacked generally horizontally, vertically or at any other angle. As shown in
As shown in
The increasing or decreasing trend of the index can be displayed as an arrow 506. The trend of the index can represent the instantaneous gradient of the graph 510. The arrow 506 can be pointing at an angle. The direction of the arrow can correspond to the increasing or decreasing trend of the patient's index. As shown in
A magnitude of the angle at which the arrow 506 points can correspond to a rate of increase or decrease of the patient's index. In
As further shown in
Turning to
The circle 608 can be empty, partially filled, or fully filled. The circle can also be a triangle, a rectangle, a diamond, or any other shape. As shown in
As shown in
The increasing or decreasing trend of index can be displayed as a pointer 606. The trend of index can be the instantaneous gradient of the index graph 610. The pointer 606 can be pointing at an angle. The direction of the pointer 606 can correspond to the increasing or decreasing trend of the patient's index. As shown in
In
The displayed indications of SpO2, the index, and/or an increasing or decreasing trend of index on the same display can provide direct visual information of the patient's oxygen state or other physiological parameters. The visual information can be easy to understand by a user upon glancing at the display and/or can reduce the need for the user to further mentally process the oxygen state indications.
In
In
In
In
In
In
In
In
The displays as shown in
In some implementations, the processor of the patient monitoring system can monitor the plateauing of the index. The processor can output alert(s) of the plateauing of the index. As shown in
The indication of the plateauing of the dissolved oxygen index can be presented in one or more forms, such as via a visual indicator, text message, and/or audio message.
In one example, the “RESERVE FULL” indication can be used to indicate the completion of a nitrogen washout performed on the patient. The nitrogen washout is a test for estimating a patient's functional residual capacity of the lungs. As the anatomical dead space of the lungs are filled (such as gradually filled) with oxygen after a nitrogen washout, any addition increase in the partial pressure of oxygen, for example, due to a higher FiO2, a higher flow rate of oxygen supply to the patient, or otherwise, can be due to more oxygen getting dissolved in the blood plasma. Accordingly, when the index does not further increase despite an increase in the oxygen supply to the patient, the nitrogen washout is likely complete on the patient. The indication can be in the form of a simple message, a visual alert, an audible alert, a warning message, or any combination of the above.
The display elements disclosed herein, such as the bar(s), arrow, circle, pointer, any of their variants, and any combinations thereof, can represent any physiological parameters, of which the dissolved oxygen index is one example. The display elements disclosed herein can be used to represent a magnitude, an increasing or decreasing trend, and/or a rate of change of any physiological parameter. When the physiological parameter is zero or outside a range that can be calculated by the patient monitoring device, the display area can show a generally horizontally pointing arrow without a bar or its equivalent, or a dial having an empty circle, or its equivalent, pointing at about 3 o'clock. Displaying indications of the magnitude and/or changes of a physiological parameter together can provide more comprehensive information about a patient's physiological conditions in a limited and/or crowded display area than displaying the magnitude and the changes of the physiological parameter separately.
Although this disclosure has been described in the context of certain embodiments and examples, it will be understood by those skilled in the art that the disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. In addition, while several variations of the embodiments of the disclosure have been shown and described in detail, other modifications, which are within the scope of this disclosure, will be readily apparent to those of skill in the art. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the disclosure. For example, features described above in connection with one embodiment can be used with a different embodiment described herein and the combination still fall within the scope of the disclosure. It should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to form varying modes of the embodiments of the disclosure. Thus, it is intended that the scope of the disclosure herein should not be limited by the particular embodiments described above. Accordingly, unless otherwise stated, or unless clearly incompatible, each embodiment of this invention may comprise, additional to its essential features described herein, one or more features as described herein from each other embodiment of the invention disclosed herein.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a subcombination or variation of a subcombination.
Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all operations be performed, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Further, the operations may be rearranged or reordered in other implementations. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, 0.1 degree, or otherwise.
The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
The present application is a continuation of U.S. patent application Ser. No. 16/175,474, filed Oct. 30, 2018, entitled “SYSTEM FOR DISPLAYING OXYGEN STATE INDICATIONS,” which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/579,575, filed Oct. 31, 2017, titled “SYSTEM FOR DISPLAYING OXYGEN STATE INDICATIONS,” incorporated herein by reference in its entirety. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.
Number | Name | Date | Kind |
---|---|---|---|
4960128 | Gordon et al. | Oct 1990 | A |
4964408 | Hink et al. | Oct 1990 | A |
5041187 | Hink et al. | Aug 1991 | A |
5069213 | Hink et al. | Dec 1991 | A |
5163438 | Gordon et al. | Nov 1992 | A |
5319355 | Russek | Jun 1994 | A |
5337744 | Branigan | Aug 1994 | A |
5341805 | Stavridi et al. | Aug 1994 | A |
5355880 | Thomas et al. | Oct 1994 | A |
D353195 | Savage et al. | Dec 1994 | S |
D353196 | Savage et al. | Dec 1994 | S |
5377676 | Vari et al. | Jan 1995 | A |
D359546 | Savage et al. | Jun 1995 | S |
5431170 | Mathews | Jul 1995 | A |
5436499 | Namavar et al. | Jul 1995 | A |
D361840 | Savage et al. | Aug 1995 | S |
D362063 | Savage et al. | Sep 1995 | S |
5452717 | Branigan et al. | Sep 1995 | A |
D363120 | Savage et al. | Oct 1995 | S |
5456252 | Vari et al. | Oct 1995 | A |
5479934 | Imran | Jan 1996 | A |
5482036 | Diab et al. | Jan 1996 | A |
5490505 | Diab et al. | Feb 1996 | A |
5494043 | O'Sullivan et al. | Feb 1996 | A |
5533511 | Kaspari et al. | Jul 1996 | A |
5534851 | Russek | Jul 1996 | A |
5561275 | Savage et al. | Oct 1996 | A |
5562002 | Lalin | Oct 1996 | A |
5590649 | Caro et al. | Jan 1997 | A |
5602924 | Durand et al. | Feb 1997 | A |
5632272 | Diab et al. | May 1997 | A |
5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
5638818 | Diab et al. | Jun 1997 | A |
5645440 | Tobler et al. | Jul 1997 | A |
5671914 | Kalkhoran et al. | Sep 1997 | A |
5685299 | Diab et al. | Nov 1997 | A |
5726440 | Kalkhoran et al. | Mar 1998 | A |
D393830 | Tobler et al. | Apr 1998 | S |
5743262 | Lepper, Jr. et al. | Apr 1998 | A |
5747806 | Khalil et al. | May 1998 | A |
5750994 | Schlager | May 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5760910 | Lepper, Jr. et al. | Jun 1998 | A |
5769785 | Diab et al. | Jun 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5785659 | Caro et al. | Jul 1998 | A |
5791347 | Flaherty et al. | Aug 1998 | A |
5810734 | Caro et al. | Sep 1998 | A |
5823950 | Diab et al. | Oct 1998 | A |
5830131 | Caro et al. | Nov 1998 | A |
5833618 | Caro et al. | Nov 1998 | A |
5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
5890929 | Mills et al. | Apr 1999 | A |
5904654 | Wohltmann et al. | May 1999 | A |
5919134 | Diab | Jul 1999 | A |
5934925 | Tobler et al. | Aug 1999 | A |
5940182 | Lepper, Jr. et al. | Aug 1999 | A |
5987343 | Kinast | Nov 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5997343 | Mills et al. | Dec 1999 | A |
6002952 | Diab et al. | Dec 1999 | A |
6010937 | Karam et al. | Jan 2000 | A |
6011986 | Diab et al. | Jan 2000 | A |
6027452 | Flaherty et al. | Feb 2000 | A |
6036642 | Diab et al. | Mar 2000 | A |
6040578 | Malin et al. | Mar 2000 | A |
6045509 | Caro et al. | Apr 2000 | A |
6066204 | Haven | May 2000 | A |
6067462 | Diab et al. | May 2000 | A |
6081735 | Diab et al. | Jun 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6110522 | Lepper, Jr. et al. | Aug 2000 | A |
6115673 | Malin et al. | Sep 2000 | A |
6124597 | Shehada et al. | Sep 2000 | A |
6128521 | Marro et al. | Oct 2000 | A |
6129675 | Jay | Oct 2000 | A |
6144868 | Parker | Nov 2000 | A |
6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
6152754 | Gerhardt et al. | Nov 2000 | A |
6157850 | Diab et al. | Dec 2000 | A |
6165005 | Mills et al. | Dec 2000 | A |
6184521 | Coffin, IV et al. | Feb 2001 | B1 |
6206830 | Diab et al. | Mar 2001 | B1 |
6229856 | Diab et al. | May 2001 | B1 |
6232609 | Snyder et al. | May 2001 | B1 |
6236872 | Diab et al. | May 2001 | B1 |
6241683 | Macklem et al. | Jun 2001 | B1 |
6253097 | Aronow et al. | Jun 2001 | B1 |
6255708 | Sudharsanan et al. | Jul 2001 | B1 |
6256523 | Diab et al. | Jul 2001 | B1 |
6263222 | Diab et al. | Jul 2001 | B1 |
6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
6280213 | Tobler et al. | Aug 2001 | B1 |
6280381 | Malin et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6301493 | Marro et al. | Oct 2001 | B1 |
6308089 | von der Ruhr et al. | Oct 2001 | B1 |
6317627 | Ennen et al. | Nov 2001 | B1 |
6321100 | Parker | Nov 2001 | B1 |
6325761 | Jay | Dec 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6343224 | Parker | Jan 2002 | B1 |
6349228 | Kiani et al. | Feb 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6371921 | Caro et al. | Apr 2002 | B1 |
6377829 | Al-Ali | Apr 2002 | B1 |
6388240 | Schulz et al. | May 2002 | B2 |
6397091 | Diab et al. | May 2002 | B2 |
6411373 | Garside et al. | Jun 2002 | B1 |
6415167 | Blank et al. | Jul 2002 | B1 |
6430437 | Marro | Aug 2002 | B1 |
6430525 | Weber et al. | Aug 2002 | B1 |
6463311 | Diab | Oct 2002 | B1 |
6470199 | Kopotic et al. | Oct 2002 | B1 |
6487429 | Hockersmith et al. | Nov 2002 | B2 |
6501975 | Diab et al. | Dec 2002 | B2 |
6505059 | Kollias et al. | Jan 2003 | B1 |
6515273 | Al-Ali | Feb 2003 | B2 |
6519487 | Parker | Feb 2003 | B1 |
6525386 | Mills et al. | Feb 2003 | B1 |
6526300 | Kiani et al. | Feb 2003 | B1 |
6534012 | Hazen et al. | Mar 2003 | B1 |
6541756 | Schulz et al. | Apr 2003 | B2 |
6542764 | Al-Ali et al. | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6587196 | Stippick et al. | Jul 2003 | B1 |
6587199 | Luu | Jul 2003 | B1 |
6595316 | Cybulski et al. | Jul 2003 | B2 |
6597932 | Tian et al. | Jul 2003 | B2 |
6597933 | Kiani et al. | Jul 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6632181 | Flaherty et al. | Oct 2003 | B2 |
6635559 | Greenwald et al. | Oct 2003 | B2 |
6639668 | Trepagnier | Oct 2003 | B1 |
6640116 | Diab | Oct 2003 | B2 |
6640117 | Makarewicz et al. | Oct 2003 | B2 |
6643530 | Diab et al. | Nov 2003 | B2 |
6650917 | Diab et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kiani et al. | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6671531 | Al-Ali | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6684091 | Parker | Jan 2004 | B2 |
6697656 | Al-Ali | Feb 2004 | B1 |
6697657 | Shehada et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
RE38476 | Diab et al. | Mar 2004 | E |
6699194 | Diab et al. | Mar 2004 | B1 |
6714804 | Al-Ali et al. | Mar 2004 | B2 |
RE38492 | Diab et al. | Apr 2004 | E |
6721582 | Trepagnier et al. | Apr 2004 | B2 |
6721585 | Parker | Apr 2004 | B1 |
6725075 | Al-Ali | Apr 2004 | B2 |
6728560 | Kollias et al. | Apr 2004 | B2 |
6735459 | Parker | May 2004 | B2 |
6738652 | Mattu et al. | May 2004 | B2 |
6743172 | Blike | Jun 2004 | B1 |
6745060 | Diab et al. | Jun 2004 | B2 |
6760607 | Al-Ali | Jul 2004 | B2 |
6770028 | Ali et al. | Aug 2004 | B1 |
6771994 | Kiani et al. | Aug 2004 | B2 |
6788965 | Ruchti et al. | Sep 2004 | B2 |
6792300 | Diab et al. | Sep 2004 | B1 |
6813511 | Diab et al. | Nov 2004 | B2 |
6816241 | Grubisic | Nov 2004 | B2 |
6816741 | Diab | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6826419 | Diab et al. | Nov 2004 | B2 |
6830711 | Mills et al. | Dec 2004 | B2 |
6850787 | Weber et al. | Feb 2005 | B2 |
6850788 | Al-Ali | Feb 2005 | B2 |
6852083 | Caro et al. | Feb 2005 | B2 |
6861639 | Al-Ali | Mar 2005 | B2 |
6876931 | Lorenz et al. | Apr 2005 | B2 |
6898452 | Al-Ali et al. | May 2005 | B2 |
6920345 | Al-Ali et al. | Jul 2005 | B2 |
6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
6934570 | Kiani et al. | Aug 2005 | B2 |
6939305 | Flaherty et al. | Sep 2005 | B2 |
6943348 | Coffin, IV | Sep 2005 | B1 |
6950687 | Al-Ali | Sep 2005 | B2 |
6956649 | Acosta et al. | Oct 2005 | B2 |
6961598 | Diab | Nov 2005 | B2 |
6970792 | Diab | Nov 2005 | B1 |
6979812 | Al-Ali | Dec 2005 | B2 |
6985764 | Mason et al. | Jan 2006 | B2 |
6990364 | Ruchti et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
6998247 | Monfre et al. | Feb 2006 | B2 |
6999904 | Weber et al. | Feb 2006 | B2 |
7003338 | Weber et al. | Feb 2006 | B2 |
7003339 | Diab et al. | Feb 2006 | B2 |
7015451 | Dalke et al. | Mar 2006 | B2 |
7024233 | Ali et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7039449 | Al-Ali | May 2006 | B2 |
7041060 | Flaherty et al. | May 2006 | B2 |
7044918 | Diab | May 2006 | B2 |
7048687 | Reuss et al. | May 2006 | B1 |
7067893 | Mills et al. | Jun 2006 | B2 |
D526719 | Richie, Jr. et al. | Aug 2006 | S |
7096052 | Mason et al. | Aug 2006 | B2 |
7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
D529616 | Deros et al. | Oct 2006 | S |
7132641 | Schulz et al. | Nov 2006 | B2 |
7133710 | Acosta et al. | Nov 2006 | B2 |
7142901 | Kiani et al. | Nov 2006 | B2 |
7149561 | Diab | Dec 2006 | B2 |
7186966 | Al-Ali | Mar 2007 | B2 |
7190261 | Al-Ali | Mar 2007 | B2 |
7215984 | Diab et al. | May 2007 | B2 |
7215986 | Diab et al. | May 2007 | B2 |
7221971 | Diab et al. | May 2007 | B2 |
7225006 | Al-Ali et al. | May 2007 | B2 |
7225007 | Al-Ali et al. | May 2007 | B2 |
RE39672 | Shehada et al. | Jun 2007 | E |
7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
7245953 | Parker | Jul 2007 | B1 |
7254429 | Schurman et al. | Aug 2007 | B2 |
7254431 | Al-Ali et al. | Aug 2007 | B2 |
7254433 | Diab et al. | Aug 2007 | B2 |
7254434 | Schulz et al. | Aug 2007 | B2 |
7272425 | Al-Ali | Sep 2007 | B2 |
7274955 | Kiani et al. | Sep 2007 | B2 |
D554263 | Al-Ali et al. | Oct 2007 | S |
7280858 | Al-Ali et al. | Oct 2007 | B2 |
7289835 | Mansfield et al. | Oct 2007 | B2 |
7292883 | De Felice et al. | Nov 2007 | B2 |
7295866 | Al-Ali | Nov 2007 | B2 |
7328053 | Diab et al. | Feb 2008 | B1 |
7332784 | Mills et al. | Feb 2008 | B2 |
7340287 | Mason et al. | Mar 2008 | B2 |
7341559 | Schulz et al. | Mar 2008 | B2 |
7343186 | Lamego et al. | Mar 2008 | B2 |
D566282 | Al-Ali et al. | Apr 2008 | S |
7355512 | Al-Ali | Apr 2008 | B1 |
7356365 | Schurman | Apr 2008 | B2 |
7371981 | Abdul-Hafiz | May 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7373194 | Weber et al. | May 2008 | B2 |
7376453 | Diab et al. | May 2008 | B1 |
7377794 | Al-Ali et al. | May 2008 | B2 |
7377899 | Weber et al. | May 2008 | B2 |
7383070 | Diab et al. | Jun 2008 | B2 |
7395158 | Monfre et al. | Jul 2008 | B2 |
7415297 | Al-Ali et al. | Aug 2008 | B2 |
7428432 | Ali et al. | Sep 2008 | B2 |
7438683 | Al-Ali et al. | Oct 2008 | B2 |
7440787 | Diab | Oct 2008 | B2 |
7454240 | Diab et al. | Nov 2008 | B2 |
7467002 | Weber et al. | Dec 2008 | B2 |
7469157 | Diab et al. | Dec 2008 | B2 |
7471969 | Diab et al. | Dec 2008 | B2 |
7471971 | Diab et al. | Dec 2008 | B2 |
7483729 | Al-Ali et al. | Jan 2009 | B2 |
7483730 | Diab et al. | Jan 2009 | B2 |
7489958 | Diab et al. | Feb 2009 | B2 |
7496391 | Diab et al. | Feb 2009 | B2 |
7496393 | Diab et al. | Feb 2009 | B2 |
D587657 | Al-Ali et al. | Mar 2009 | S |
7499741 | Diab et al. | Mar 2009 | B2 |
7499835 | Weber et al. | Mar 2009 | B2 |
7500950 | Al-Ali et al. | Mar 2009 | B2 |
7509154 | Diab et al. | Mar 2009 | B2 |
7509494 | Al-Ali | Mar 2009 | B2 |
7510849 | Schurman et al. | Mar 2009 | B2 |
7514725 | Wojtczuk et al. | Apr 2009 | B2 |
7519406 | Blank et al. | Apr 2009 | B2 |
7526328 | Diab et al. | Apr 2009 | B2 |
D592507 | Wachman et al. | May 2009 | S |
7530942 | Diab | May 2009 | B1 |
7530949 | Al Ali et al. | May 2009 | B2 |
7530955 | Diab et al. | May 2009 | B2 |
7563110 | Al-Ali et al. | Jul 2009 | B2 |
7593230 | Abul-Haj et al. | Sep 2009 | B2 |
7596398 | Al-Ali et al. | Sep 2009 | B2 |
7606608 | Blank et al. | Oct 2009 | B2 |
7618375 | Flaherty et al. | Nov 2009 | B2 |
7620674 | Ruchti et al. | Nov 2009 | B2 |
D606659 | Kiani et al. | Dec 2009 | S |
7629039 | Eckerbom et al. | Dec 2009 | B2 |
7640140 | Ruchti et al. | Dec 2009 | B2 |
7647083 | Al-Ali et al. | Jan 2010 | B2 |
D609193 | Al-Ali et al. | Feb 2010 | S |
D614305 | Al-Ali et al. | Apr 2010 | S |
7697966 | Monfre et al. | Apr 2010 | B2 |
7698105 | Ruchti et al. | Apr 2010 | B2 |
RE41317 | Parker | May 2010 | E |
RE41333 | Blank et al. | May 2010 | E |
7729733 | Al-Ali et al. | Jun 2010 | B2 |
7734320 | Al-Ali | Jun 2010 | B2 |
7761127 | Al-Ali et al. | Jul 2010 | B2 |
7761128 | Al-Ali et al. | Jul 2010 | B2 |
7764982 | Dalke et al. | Jul 2010 | B2 |
D621516 | Kiani et al. | Aug 2010 | S |
7791155 | Diab | Sep 2010 | B2 |
7801581 | Diab | Sep 2010 | B2 |
7822452 | Schurman et al. | Oct 2010 | B2 |
RE41912 | Parker | Nov 2010 | E |
7844313 | Kiani et al. | Nov 2010 | B2 |
7844314 | Al-Ali | Nov 2010 | B2 |
7844315 | Al-Ali | Nov 2010 | B2 |
7865222 | Weber et al. | Jan 2011 | B2 |
7873497 | Weber et al. | Jan 2011 | B2 |
7880606 | Al-Ali | Feb 2011 | B2 |
7880626 | Al-Ali et al. | Feb 2011 | B2 |
7891355 | Al-Ali et al. | Feb 2011 | B2 |
7894868 | Al-Ali et al. | Feb 2011 | B2 |
7899507 | Al-Ali et al. | Mar 2011 | B2 |
7899518 | Trepagnier et al. | Mar 2011 | B2 |
7904132 | Weber et al. | Mar 2011 | B2 |
7909772 | Popov et al. | Mar 2011 | B2 |
7910875 | Al-Ali | Mar 2011 | B2 |
7919713 | Al-Ali et al. | Apr 2011 | B2 |
7937128 | Al-Ali | May 2011 | B2 |
7937129 | Mason et al. | May 2011 | B2 |
7937130 | Diab et al. | May 2011 | B2 |
7941199 | Kiani | May 2011 | B2 |
7951086 | Flaherty et al. | May 2011 | B2 |
7957780 | Lamego et al. | Jun 2011 | B2 |
7962188 | Kiani et al. | Jun 2011 | B2 |
7962190 | Diab et al. | Jun 2011 | B1 |
7976472 | Kiani | Jul 2011 | B2 |
7988637 | Diab | Aug 2011 | B2 |
7990382 | Kiani | Aug 2011 | B2 |
7991446 | Ali et al. | Aug 2011 | B2 |
8000761 | Al-Ali | Aug 2011 | B2 |
8008088 | Bellott et al. | Aug 2011 | B2 |
RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
8019400 | Diab et al. | Sep 2011 | B2 |
8028701 | Al-Ali et al. | Oct 2011 | B2 |
8029765 | Bellott et al. | Oct 2011 | B2 |
8036727 | Schurman et al. | Oct 2011 | B2 |
8036728 | Diab et al. | Oct 2011 | B2 |
8046040 | Ali et al. | Oct 2011 | B2 |
8046041 | Diab et al. | Oct 2011 | B2 |
8046042 | Diab et al. | Oct 2011 | B2 |
8048040 | Kiani | Nov 2011 | B2 |
8050728 | Al-Ali et al. | Nov 2011 | B2 |
RE43169 | Parker | Feb 2012 | E |
8118620 | Al-Ali et al. | Feb 2012 | B2 |
8126528 | Diab et al. | Feb 2012 | B2 |
8128572 | Diab et al. | Mar 2012 | B2 |
8130105 | Al-Ali et al. | Mar 2012 | B2 |
8145287 | Diab et al. | Mar 2012 | B2 |
8150487 | Diab et al. | Apr 2012 | B2 |
8175672 | Parker | May 2012 | B2 |
8180420 | Diab et al. | May 2012 | B2 |
8182443 | Kiani | May 2012 | B1 |
8185180 | Diab et al. | May 2012 | B2 |
8190223 | Al-Ali et al. | May 2012 | B2 |
8190227 | Diab et al. | May 2012 | B2 |
8203438 | Kiani et al. | Jun 2012 | B2 |
8203704 | Merritt et al. | Jun 2012 | B2 |
8204566 | Schurman et al. | Jun 2012 | B2 |
8219172 | Schurman et al. | Jul 2012 | B2 |
8224411 | Al-Ali et al. | Jul 2012 | B2 |
8228181 | Al-Ali | Jul 2012 | B2 |
8229532 | Davis | Jul 2012 | B2 |
8229533 | Diab et al. | Jul 2012 | B2 |
8233955 | Al-Ali et al. | Jul 2012 | B2 |
8244325 | Al-Ali et al. | Aug 2012 | B2 |
8255026 | Al-Ali | Aug 2012 | B1 |
8255027 | Al-Ali et al. | Aug 2012 | B2 |
8255028 | Al-Ali et al. | Aug 2012 | B2 |
D667842 | Ouilhet | Sep 2012 | S |
8260577 | Weber et al. | Sep 2012 | B2 |
8265723 | McHale et al. | Sep 2012 | B1 |
8274360 | Sampath et al. | Sep 2012 | B2 |
8280473 | Al-Ali | Oct 2012 | B2 |
8301217 | Al-Ali et al. | Oct 2012 | B2 |
8306596 | Schurman et al. | Nov 2012 | B2 |
8310336 | Muhsin et al. | Nov 2012 | B2 |
8315683 | Al-Ali et al. | Nov 2012 | B2 |
RE43860 | Parker | Dec 2012 | E |
8337403 | Al-Ali et al. | Dec 2012 | B2 |
8346330 | Lamego | Jan 2013 | B2 |
8353842 | Al-Ali et al. | Jan 2013 | B2 |
8355766 | MacNeish, III et al. | Jan 2013 | B2 |
8359080 | Diab et al. | Jan 2013 | B2 |
8364223 | Al-Ali et al. | Jan 2013 | B2 |
8364226 | Diab et al. | Jan 2013 | B2 |
8374665 | Lamego | Feb 2013 | B2 |
8385995 | Al-Ali et al. | Feb 2013 | B2 |
8385996 | Smith et al. | Feb 2013 | B2 |
8388353 | Kiani et al. | Mar 2013 | B2 |
8399822 | Al-Ali | Mar 2013 | B2 |
8401602 | Kiani | Mar 2013 | B2 |
8405608 | Al-Ali et al. | Mar 2013 | B2 |
8414499 | Al-Ali et al. | Apr 2013 | B2 |
8418524 | Al-Ali | Apr 2013 | B2 |
8423106 | Lamego et al. | Apr 2013 | B2 |
8428967 | Olsen et al. | Apr 2013 | B2 |
8430817 | Al-Ali et al. | Apr 2013 | B1 |
8437825 | Dalvi et al. | May 2013 | B2 |
8455290 | Siskavich | Jun 2013 | B2 |
8457703 | Al-Ali | Jun 2013 | B2 |
8457707 | Kiani | Jun 2013 | B2 |
8463349 | Diab et al. | Jun 2013 | B2 |
8466286 | Bellott et al. | Jun 2013 | B2 |
8471713 | Poeze et al. | Jun 2013 | B2 |
8473020 | Kiani et al. | Jun 2013 | B2 |
8483787 | Al-Ali et al. | Jul 2013 | B2 |
8489364 | Weber et al. | Jul 2013 | B2 |
8498684 | Weber et al. | Jul 2013 | B2 |
8504128 | Blank et al. | Aug 2013 | B2 |
8509867 | Workman et al. | Aug 2013 | B2 |
8515509 | Bruinsma et al. | Aug 2013 | B2 |
D689091 | Impas et al. | Sep 2013 | S |
8523781 | Al-Ali | Sep 2013 | B2 |
8529301 | Al-Ali et al. | Sep 2013 | B2 |
8532727 | Ali et al. | Sep 2013 | B2 |
8532728 | Diab et al. | Sep 2013 | B2 |
D692145 | Al-Ali et al. | Oct 2013 | S |
8547209 | Kiani et al. | Oct 2013 | B2 |
8548548 | Al-Ali | Oct 2013 | B2 |
8548549 | Schurman et al. | Oct 2013 | B2 |
8548550 | Al-Ali et al. | Oct 2013 | B2 |
8560032 | Al-Ali et al. | Oct 2013 | B2 |
8560034 | Diab et al. | Oct 2013 | B1 |
8570167 | Al-Ali | Oct 2013 | B2 |
8570503 | Vo et al. | Oct 2013 | B2 |
8571617 | Reichgott et al. | Oct 2013 | B2 |
8571618 | Lamego et al. | Oct 2013 | B1 |
8571619 | Al-Ali et al. | Oct 2013 | B2 |
D693365 | Gardner et al. | Nov 2013 | S |
8577431 | Lamego et al. | Nov 2013 | B2 |
8577433 | McKenna | Nov 2013 | B2 |
8581732 | Al-Ali et al. | Nov 2013 | B2 |
8584345 | Al-Ali et al. | Nov 2013 | B2 |
8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
8600467 | Al-Ali et al. | Dec 2013 | B2 |
8606342 | Diab | Dec 2013 | B2 |
8626255 | Al-Ali et al. | Jan 2014 | B2 |
8630691 | Lamego et al. | Jan 2014 | B2 |
8634889 | Al-Ali et al. | Jan 2014 | B2 |
8641631 | Sierra et al. | Feb 2014 | B2 |
8652060 | Al-Ali | Feb 2014 | B2 |
8663107 | Kiani | Mar 2014 | B2 |
8666468 | Al-Ali | Mar 2014 | B1 |
8667967 | Al-Ali et al. | Mar 2014 | B2 |
8670811 | O'Reilly | Mar 2014 | B2 |
8670814 | Diab et al. | Mar 2014 | B2 |
8676286 | Weber et al. | Mar 2014 | B2 |
8682407 | Al-Ali | Mar 2014 | B2 |
RE44823 | Parker | Apr 2014 | E |
RE44875 | Kiani et al. | Apr 2014 | E |
8688183 | Bruinsma et al. | Apr 2014 | B2 |
8690799 | Telfort et al. | Apr 2014 | B2 |
8700112 | Kiani | Apr 2014 | B2 |
8702627 | Telfort et al. | Apr 2014 | B2 |
8706179 | Parker | Apr 2014 | B2 |
8712494 | MacNeish, III et al. | Apr 2014 | B1 |
8715206 | Telfort et al. | May 2014 | B2 |
8718735 | Lamego et al. | May 2014 | B2 |
8718737 | Diab et al. | May 2014 | B2 |
8718738 | Blank et al. | May 2014 | B2 |
8720249 | Al-Ali | May 2014 | B2 |
8721541 | Al-Ali et al. | May 2014 | B2 |
8721542 | Al-Ali et al. | May 2014 | B2 |
8723677 | Kiani | May 2014 | B1 |
8740792 | Kiani et al. | Jun 2014 | B1 |
8754776 | Poeze et al. | Jun 2014 | B2 |
8755535 | Telfort et al. | Jun 2014 | B2 |
8755856 | Diab et al. | Jun 2014 | B2 |
8755872 | Marinow | Jun 2014 | B1 |
8761850 | Lamego | Jun 2014 | B2 |
8764671 | Kiani | Jul 2014 | B2 |
8768423 | Shakespeare et al. | Jul 2014 | B2 |
8771204 | Telfort et al. | Jul 2014 | B2 |
8777634 | Kiani et al. | Jul 2014 | B2 |
8781543 | Diab et al. | Jul 2014 | B2 |
8781544 | Al-Ali et al. | Jul 2014 | B2 |
8781549 | Al-Ali et al. | Jul 2014 | B2 |
8788003 | Schurman et al. | Jul 2014 | B2 |
8790268 | Al-Ali | Jul 2014 | B2 |
8801613 | Al-Ali et al. | Aug 2014 | B2 |
8821397 | Al-Ali et al. | Sep 2014 | B2 |
8821415 | Al-Ali et al. | Sep 2014 | B2 |
8830449 | Lamego et al. | Sep 2014 | B1 |
8831700 | Schurman et al. | Sep 2014 | B2 |
8840549 | Al-Ali et al. | Sep 2014 | B2 |
8847740 | Kiani et al. | Sep 2014 | B2 |
8849365 | Smith et al. | Sep 2014 | B2 |
8852094 | Al-Ali et al. | Oct 2014 | B2 |
8852994 | Wojtczuk et al. | Oct 2014 | B2 |
8868147 | Stippick et al. | Oct 2014 | B2 |
8868150 | Al-Ali et al. | Oct 2014 | B2 |
8870792 | Al-Ali et al. | Oct 2014 | B2 |
8886271 | Kiani et al. | Nov 2014 | B2 |
8888539 | Al-Ali et al. | Nov 2014 | B2 |
8888708 | Diab et al. | Nov 2014 | B2 |
8892180 | Weber et al. | Nov 2014 | B2 |
8897847 | Al-Ali | Nov 2014 | B2 |
8909310 | Lamego et al. | Dec 2014 | B2 |
8911377 | Al-Ali | Dec 2014 | B2 |
8912909 | Al-Ali et al. | Dec 2014 | B2 |
8920317 | Al-Ali et al. | Dec 2014 | B2 |
8921699 | Al-Ali et al. | Dec 2014 | B2 |
8922382 | Al-Ali et al. | Dec 2014 | B2 |
8929964 | Al-Ali et al. | Jan 2015 | B2 |
8942777 | Diab et al. | Jan 2015 | B2 |
8948834 | Diab et al. | Feb 2015 | B2 |
8948835 | Diab | Feb 2015 | B2 |
8965471 | Lamego | Feb 2015 | B2 |
8983564 | Al-Ali | Mar 2015 | B2 |
8989831 | Al-Ali et al. | Mar 2015 | B2 |
8996085 | Kiani et al. | Mar 2015 | B2 |
8998809 | Kiani | Apr 2015 | B2 |
9028429 | Telfort et al. | May 2015 | B2 |
9037207 | Al-Ali et al. | May 2015 | B2 |
9060721 | Reichgott et al. | Jun 2015 | B2 |
9066666 | Kiani | Jun 2015 | B2 |
9066680 | Al-Ali et al. | Jun 2015 | B1 |
9072474 | Al-Ali et al. | Jul 2015 | B2 |
9078560 | Schurman et al. | Jul 2015 | B2 |
9084569 | Weber et al. | Jul 2015 | B2 |
9095316 | Welch et al. | Aug 2015 | B2 |
9106038 | Telfort et al. | Aug 2015 | B2 |
9107625 | Telfort et al. | Aug 2015 | B2 |
9107626 | Al-Ali et al. | Aug 2015 | B2 |
9113831 | Al-Ali | Aug 2015 | B2 |
9113832 | Al-Ali | Aug 2015 | B2 |
9119595 | Lamego | Sep 2015 | B2 |
9131881 | Diab et al. | Sep 2015 | B2 |
9131882 | Al-Ali et al. | Sep 2015 | B2 |
9131883 | Al-Ali | Sep 2015 | B2 |
9131917 | Telfort et al. | Sep 2015 | B2 |
9138180 | Coverston et al. | Sep 2015 | B1 |
9138182 | Al-Ali et al. | Sep 2015 | B2 |
9138192 | Weber et al. | Sep 2015 | B2 |
9142117 | Muhsin et al. | Sep 2015 | B2 |
9153112 | Kiani et al. | Oct 2015 | B1 |
9153121 | Kiani et al. | Oct 2015 | B2 |
9161696 | Al-Ali et al. | Oct 2015 | B2 |
9161713 | Al-Ali et al. | Oct 2015 | B2 |
9167995 | Lamego et al. | Oct 2015 | B2 |
9176141 | Al-Ali et al. | Nov 2015 | B2 |
9186102 | Bruinsma et al. | Nov 2015 | B2 |
9192312 | Al-Ali | Nov 2015 | B2 |
9192329 | Al-Ali | Nov 2015 | B2 |
9192351 | Telfort et al. | Nov 2015 | B1 |
9195385 | Al-Ali et al. | Nov 2015 | B2 |
D745046 | Shin et al. | Dec 2015 | S |
9211072 | Kiani | Dec 2015 | B2 |
9211095 | Al-Ali | Dec 2015 | B1 |
9218454 | Kiani et al. | Dec 2015 | B2 |
9226696 | Kiani | Jan 2016 | B2 |
9241662 | Al-Ali et al. | Jan 2016 | B2 |
9245668 | Vo et al. | Jan 2016 | B1 |
9259185 | Abdul-Hafiz et al. | Feb 2016 | B2 |
9267572 | Barker et al. | Feb 2016 | B2 |
9277880 | Poeze et al. | Mar 2016 | B2 |
9289167 | Diab et al. | Mar 2016 | B2 |
9295421 | Kiani et al. | Mar 2016 | B2 |
D753716 | Torres et al. | Apr 2016 | S |
9307928 | Al-Ali et al. | Apr 2016 | B1 |
9323894 | Kiani | Apr 2016 | B2 |
D755392 | Hwang et al. | May 2016 | S |
9326712 | Kiani | May 2016 | B1 |
9333316 | Kiani | May 2016 | B2 |
9339220 | Lamego et al. | May 2016 | B2 |
9341565 | Lamego et al. | May 2016 | B2 |
9351673 | Diab et al. | May 2016 | B2 |
9351675 | Al-Ali et al. | May 2016 | B2 |
9364181 | Kiani et al. | Jun 2016 | B2 |
9368671 | Wojtczuk et al. | Jun 2016 | B2 |
9370325 | Al-Ali et al. | Jun 2016 | B2 |
9370326 | McHale et al. | Jun 2016 | B2 |
9370335 | Al-Ali et al. | Jun 2016 | B2 |
9375185 | Ali et al. | Jun 2016 | B2 |
9386953 | Al-Ali | Jul 2016 | B2 |
9386961 | Al-Ali et al. | Jul 2016 | B2 |
9392945 | Al-Ali et al. | Jul 2016 | B2 |
9397448 | Al-Ali et al. | Jul 2016 | B2 |
D763317 | Kim et al. | Aug 2016 | S |
9408542 | Kinast et al. | Aug 2016 | B1 |
9436645 | Al-Ali et al. | Sep 2016 | B2 |
9445759 | Lamego et al. | Sep 2016 | B1 |
9466919 | Kiani et al. | Oct 2016 | B2 |
9474474 | Lamego et al. | Oct 2016 | B2 |
D772931 | Vulk et al. | Nov 2016 | S |
9480422 | Al-Ali | Nov 2016 | B2 |
9480435 | Olsen | Nov 2016 | B2 |
9492110 | Al-Ali et al. | Nov 2016 | B2 |
9510779 | Poeze et al. | Dec 2016 | B2 |
9517024 | Kiani et al. | Dec 2016 | B2 |
D775663 | Akana et al. | Jan 2017 | S |
9532722 | Lamego et al. | Jan 2017 | B2 |
9538949 | Al-Ali et al. | Jan 2017 | B2 |
9538980 | Telfort et al. | Jan 2017 | B2 |
9549696 | Lamego et al. | Jan 2017 | B2 |
9554737 | Schurman et al. | Jan 2017 | B2 |
9560996 | Kiani | Feb 2017 | B2 |
9560998 | Al-Ali et al. | Feb 2017 | B2 |
9566019 | Al-Ali et al. | Feb 2017 | B2 |
9579039 | Jansen et al. | Feb 2017 | B2 |
9591975 | Dalvi et al. | Mar 2017 | B2 |
9622692 | Lamego et al. | Apr 2017 | B2 |
9622693 | Diab | Apr 2017 | B2 |
D788312 | Al-Ali et al. | May 2017 | S |
9636055 | Al Ali et al. | May 2017 | B2 |
9636056 | Al-Ali | May 2017 | B2 |
9649054 | Lamego et al. | May 2017 | B2 |
9662052 | Al-Ali et al. | May 2017 | B2 |
9668679 | Schurman et al. | Jun 2017 | B2 |
9668680 | Bruinsma et al. | Jun 2017 | B2 |
9668703 | Al-Ali | Jun 2017 | B2 |
9675286 | Diab | Jun 2017 | B2 |
9687160 | Kiani | Jun 2017 | B2 |
9693719 | Al-Ali et al. | Jul 2017 | B2 |
9693737 | Al-Ali | Jul 2017 | B2 |
9697928 | Al-Ali et al. | Jul 2017 | B2 |
9717425 | Kiani et al. | Aug 2017 | B2 |
9717458 | Lamego et al. | Aug 2017 | B2 |
9724016 | Al-Ali et al. | Aug 2017 | B1 |
9724024 | Al-Ali | Aug 2017 | B2 |
9724025 | Kiani et al. | Aug 2017 | B1 |
9730640 | Diab et al. | Aug 2017 | B2 |
9743887 | Al-Ali et al. | Aug 2017 | B2 |
9749232 | Sampath et al. | Aug 2017 | B2 |
9750442 | Olsen | Sep 2017 | B2 |
9750443 | Smith et al. | Sep 2017 | B2 |
9750461 | Telfort | Sep 2017 | B1 |
9775545 | Al-Ali et al. | Oct 2017 | B2 |
9775546 | Diab et al. | Oct 2017 | B2 |
9775570 | Al-Ali | Oct 2017 | B2 |
9778079 | Al-Ali et al. | Oct 2017 | B1 |
9782077 | Lamego et al. | Oct 2017 | B2 |
9782110 | Kiani | Oct 2017 | B2 |
9787568 | Lamego et al. | Oct 2017 | B2 |
9788735 | Al-Ali | Oct 2017 | B2 |
9788768 | Al-Ali et al. | Oct 2017 | B2 |
9795300 | Al-Ali | Oct 2017 | B2 |
9795310 | Al-Ali | Oct 2017 | B2 |
9795358 | Telfort et al. | Oct 2017 | B2 |
9795739 | Al-Ali et al. | Oct 2017 | B2 |
9801556 | Kiani | Oct 2017 | B2 |
9801588 | Weber et al. | Oct 2017 | B2 |
9808188 | Perea et al. | Nov 2017 | B1 |
9814418 | Weber et al. | Nov 2017 | B2 |
9820691 | Kiani | Nov 2017 | B2 |
9833152 | Kiani et al. | Dec 2017 | B2 |
9833180 | Shakespeare et al. | Dec 2017 | B2 |
9839379 | Al-Ali et al. | Dec 2017 | B2 |
9839381 | Weber et al. | Dec 2017 | B1 |
9847002 | Kiani et al. | Dec 2017 | B2 |
9847749 | Kiani et al. | Dec 2017 | B2 |
9848800 | Lee et al. | Dec 2017 | B1 |
9848806 | Al-Ali | Dec 2017 | B2 |
9848807 | Lamego | Dec 2017 | B2 |
9861298 | Eckerbom et al. | Jan 2018 | B2 |
9861304 | Al-Ali et al. | Jan 2018 | B2 |
9861305 | Weber et al. | Jan 2018 | B1 |
9867578 | Al-Ali et al. | Jan 2018 | B2 |
9872623 | Al-Ali | Jan 2018 | B2 |
9876320 | Coverston et al. | Jan 2018 | B2 |
9877650 | Muhsin et al. | Jan 2018 | B2 |
9877686 | Al-Ali et al. | Jan 2018 | B2 |
9891079 | Dalvi | Feb 2018 | B2 |
9895107 | Al-Ali et al. | Feb 2018 | B2 |
9913617 | Al-Ali et al. | Mar 2018 | B2 |
9924893 | Schurman et al. | Mar 2018 | B2 |
9924897 | Abdul-Hafiz | Mar 2018 | B1 |
9936917 | Poeze et al. | Apr 2018 | B2 |
9943269 | Muhsin et al. | Apr 2018 | B2 |
9949676 | Al-Ali | Apr 2018 | B2 |
9955937 | Telfort | May 2018 | B2 |
9965946 | Al-Ali et al. | May 2018 | B2 |
9980667 | Kiani et al. | May 2018 | B2 |
D819660 | Cabrera, Jr. et al. | Jun 2018 | S |
D820865 | Muhsin et al. | Jun 2018 | S |
9986919 | Lamego et al. | Jun 2018 | B2 |
9986952 | Dalvi et al. | Jun 2018 | B2 |
9989560 | Poeze et al. | Jun 2018 | B2 |
9993207 | Al-Ali et al. | Jun 2018 | B2 |
10007758 | Al-Ali et al. | Jun 2018 | B2 |
D822215 | Al-Ali et al. | Jul 2018 | S |
D822216 | Barker et al. | Jul 2018 | S |
10010276 | Al-Ali et al. | Jul 2018 | B2 |
10032002 | Kiani et al. | Jul 2018 | B2 |
10039482 | Al-Ali et al. | Aug 2018 | B2 |
10052037 | Kinast et al. | Aug 2018 | B2 |
10058275 | Al-Ali et al. | Aug 2018 | B2 |
10064562 | Al-Ali | Sep 2018 | B2 |
10086138 | Novak, Jr. | Oct 2018 | B1 |
10092200 | Al-Ali et al. | Oct 2018 | B2 |
10092249 | Kiani et al. | Oct 2018 | B2 |
10098550 | Al-Ali et al. | Oct 2018 | B2 |
10098591 | Al-Ali et al. | Oct 2018 | B2 |
10098610 | Al-Ali et al. | Oct 2018 | B2 |
10111591 | Dyell et al. | Oct 2018 | B2 |
D833624 | DeJong et al. | Nov 2018 | S |
10123726 | Al-Ali et al. | Nov 2018 | B2 |
10123729 | Dyell et al. | Nov 2018 | B2 |
10130289 | Al-Ali et al. | Nov 2018 | B2 |
10130291 | Schurman et al. | Nov 2018 | B2 |
D835282 | Barker et al. | Dec 2018 | S |
D835283 | Barker et al. | Dec 2018 | S |
D835284 | Barker et al. | Dec 2018 | S |
D835285 | Barker et al. | Dec 2018 | S |
10149616 | Al-Ali et al. | Dec 2018 | B2 |
10154815 | Al-Ali et al. | Dec 2018 | B2 |
10159412 | Lamego et al. | Dec 2018 | B2 |
10188296 | Al-Ali et al. | Jan 2019 | B2 |
10188331 | Kiani et al. | Jan 2019 | B1 |
10188348 | Al-Ali et al. | Jan 2019 | B2 |
RE47218 | Al-Ali | Feb 2019 | E |
RE47244 | Kiani et al. | Feb 2019 | E |
RE47249 | Kiani et al. | Feb 2019 | E |
10194847 | Al-Ali | Feb 2019 | B2 |
10194848 | Kiani et al. | Feb 2019 | B1 |
10201298 | Al-Ali et al. | Feb 2019 | B2 |
10205272 | Kiani et al. | Feb 2019 | B2 |
10205291 | Scruggs et al. | Feb 2019 | B2 |
10213108 | Al-Ali | Feb 2019 | B2 |
10219706 | Al-Ali | Mar 2019 | B2 |
10219746 | McHale et al. | Mar 2019 | B2 |
10226187 | Al-Ali et al. | Mar 2019 | B2 |
10231657 | Al-Ali et al. | Mar 2019 | B2 |
10231670 | Blank et al. | Mar 2019 | B2 |
RE47353 | Kiani et al. | Apr 2019 | E |
D844642 | Cabrera, Jr. et al. | Apr 2019 | S |
10279247 | Kiani | May 2019 | B2 |
10292664 | Al-Ali | May 2019 | B2 |
10299720 | Brown et al. | May 2019 | B2 |
10327337 | Schmidt et al. | Jun 2019 | B2 |
10327713 | Barker et al. | Jun 2019 | B2 |
10332630 | Al-Ali | Jun 2019 | B2 |
10383520 | Wojtczuk et al. | Aug 2019 | B2 |
10383527 | Al-Ali | Aug 2019 | B2 |
10388120 | Muhsin et al. | Aug 2019 | B2 |
10402650 | Suiter et al. | Sep 2019 | B1 |
D864120 | Forrest et al. | Oct 2019 | S |
10441181 | Telfort et al. | Oct 2019 | B1 |
10441196 | Eckerbom et al. | Oct 2019 | B2 |
10448844 | Al-Ali et al. | Oct 2019 | B2 |
10448871 | Al-Ali et al. | Oct 2019 | B2 |
10456038 | Lamego et al. | Oct 2019 | B2 |
10463340 | Telfort et al. | Nov 2019 | B2 |
10471159 | Lapotko et al. | Nov 2019 | B1 |
D870773 | Marrufo | Dec 2019 | S |
10505311 | Al-Ali et al. | Dec 2019 | B2 |
10524738 | Olsen | Jan 2020 | B2 |
10532174 | Al-Ali | Jan 2020 | B2 |
10537285 | Shreim et al. | Jan 2020 | B2 |
10542903 | Al-Ali et al. | Jan 2020 | B2 |
10555678 | Dalvi et al. | Feb 2020 | B2 |
10568553 | O'Neil et al. | Feb 2020 | B2 |
RE47882 | Al-Ali | Mar 2020 | E |
10608817 | Haider et al. | Mar 2020 | B2 |
D880477 | Forrest et al. | Apr 2020 | S |
10617302 | Al-Ali et al. | Apr 2020 | B2 |
10617335 | Al-Ali et al. | Apr 2020 | B2 |
10637181 | Al-Ali et al. | Apr 2020 | B2 |
D886849 | Muhsin et al. | Jun 2020 | S |
D887548 | Abdul-Hafiz et al. | Jun 2020 | S |
D887549 | Abdul-Hafiz et al. | Jun 2020 | S |
10667764 | Ahmed et al. | Jun 2020 | B2 |
D890708 | Forrest et al. | Jul 2020 | S |
10721785 | Al-Ali | Jul 2020 | B2 |
10736518 | Al-Ali et al. | Aug 2020 | B2 |
10750984 | Pauley et al. | Aug 2020 | B2 |
D897098 | Al-Ali | Sep 2020 | S |
10779098 | Iswanto et al. | Sep 2020 | B2 |
10827961 | Iyengar et al. | Nov 2020 | B1 |
10828007 | Telfort et al. | Nov 2020 | B1 |
10832818 | Muhsin et al. | Nov 2020 | B2 |
10849554 | Shreim et al. | Dec 2020 | B2 |
10856750 | Indorf et al. | Dec 2020 | B2 |
D906970 | Forrest et al. | Jan 2021 | S |
D908213 | Abdul-Hafiz et al. | Jan 2021 | S |
10918281 | Al-Ali et al. | Feb 2021 | B2 |
10932705 | Muhsin et al. | Mar 2021 | B2 |
10932729 | Kiani et al. | Mar 2021 | B2 |
10939878 | Kiani et al. | Mar 2021 | B2 |
10956950 | Al-Ali et al. | Mar 2021 | B2 |
D916135 | Indorf et al. | Apr 2021 | S |
D917046 | Abdul-Hafiz et al. | Apr 2021 | S |
D917550 | Indorf et al. | Apr 2021 | S |
D917564 | Indorf et al. | Apr 2021 | S |
D917704 | Al-Ali et al. | Apr 2021 | S |
10987066 | Chandran et al. | Apr 2021 | B2 |
10991135 | Al-Ali et al. | Apr 2021 | B2 |
D919094 | Al-Ali et al. | May 2021 | S |
D919100 | Al-Ali et al. | May 2021 | S |
11006867 | Al-Ali | May 2021 | B2 |
D921202 | Al-Ali et al. | Jun 2021 | S |
11024064 | Muhsin et al. | Jun 2021 | B2 |
11026604 | Chen et al. | Jun 2021 | B2 |
D925597 | Chandran et al. | Jul 2021 | S |
D927699 | Al-Ali et al. | Aug 2021 | S |
11076777 | Lee et al. | Aug 2021 | B2 |
11114188 | Poeze et al. | Sep 2021 | B2 |
D933232 | Al-Ali et al. | Oct 2021 | S |
D933233 | Al-Ali et al. | Oct 2021 | S |
D933234 | Al-Ali et al. | Oct 2021 | S |
11145408 | Sampath et al. | Oct 2021 | B2 |
11147518 | Al-Ali et al. | Oct 2021 | B1 |
11185262 | Al-Ali et al. | Nov 2021 | B2 |
11191484 | Kiani et al. | Dec 2021 | B2 |
D946596 | Ahmed | Mar 2022 | S |
D946597 | Ahmed | Mar 2022 | S |
D946598 | Ahmed | Mar 2022 | S |
D946617 | Ahmed | Mar 2022 | S |
11272839 | Al-Ali et al. | Mar 2022 | B2 |
11289199 | Al-Ali | Mar 2022 | B2 |
RE49034 | Al-Ali | Apr 2022 | E |
11298021 | Muhsin et al. | Apr 2022 | B2 |
D950580 | Ahmed | May 2022 | S |
D950599 | Ahmed | May 2022 | S |
D950738 | Al-Ali et al. | May 2022 | S |
D957648 | Al-Ali | Jul 2022 | S |
11389093 | Triman et al. | Jul 2022 | B2 |
11406286 | Al-Ali et al. | Aug 2022 | B2 |
11417426 | Muhsin et al. | Aug 2022 | B2 |
11439329 | Lamego | Sep 2022 | B2 |
11445948 | Scruggs et al. | Sep 2022 | B2 |
D965789 | Al-Ali et al. | Oct 2022 | S |
D967433 | Al-Ali et al. | Oct 2022 | S |
11464410 | Muhsin | Oct 2022 | B2 |
11504058 | Sharma et al. | Nov 2022 | B1 |
11504066 | Dalvi et al. | Nov 2022 | B1 |
D971933 | Ahmed | Dec 2022 | S |
D973072 | Ahmed | Dec 2022 | S |
D973685 | Ahmed | Dec 2022 | S |
D973686 | Ahmed | Dec 2022 | S |
D974193 | Forrest et al. | Jan 2023 | S |
D979516 | Al-Ali et al. | Feb 2023 | S |
D980091 | Forrest et al. | Mar 2023 | S |
11596363 | Lamego | Mar 2023 | B2 |
11627919 | Kiani et al. | Apr 2023 | B2 |
11637437 | Al-Ali et al. | Apr 2023 | B2 |
D989112 | Muhsin et al. | Jun 2023 | S |
D998625 | Indorf et al. | Sep 2023 | S |
D998630 | Indorf et al. | Sep 2023 | S |
D998631 | Indorf et al. | Sep 2023 | S |
D999244 | Indorf et al. | Sep 2023 | S |
D999245 | Indorf et al. | Sep 2023 | S |
D999246 | Indorf et al. | Sep 2023 | S |
20010034477 | Mansfield et al. | Oct 2001 | A1 |
20010039483 | Brand et al. | Nov 2001 | A1 |
20020010401 | Bushmakin et al. | Jan 2002 | A1 |
20020058864 | Mansfield et al. | May 2002 | A1 |
20020133080 | Apruzzese et al. | Sep 2002 | A1 |
20030013975 | Kiani | Jan 2003 | A1 |
20030018243 | Gerhardt et al. | Jan 2003 | A1 |
20030144582 | Cohen et al. | Jul 2003 | A1 |
20030156288 | Barnum et al. | Aug 2003 | A1 |
20030212312 | Coffin, IV et al. | Nov 2003 | A1 |
20040106163 | Workman, Jr. et al. | Jun 2004 | A1 |
20050055276 | Kiani et al. | Mar 2005 | A1 |
20050234317 | Kiani | Oct 2005 | A1 |
20060073719 | Kiani | Apr 2006 | A1 |
20060074321 | Kouchi et al. | Apr 2006 | A1 |
20060161054 | Reuss et al. | Jul 2006 | A1 |
20060189871 | Al-Ali et al. | Aug 2006 | A1 |
20070073116 | Kiani et al. | Mar 2007 | A1 |
20070180140 | Welch et al. | Aug 2007 | A1 |
20070244377 | Cozad et al. | Oct 2007 | A1 |
20070282478 | Al-Ali et al. | Dec 2007 | A1 |
20080064965 | Jay et al. | Mar 2008 | A1 |
20080094228 | Welch et al. | Apr 2008 | A1 |
20080221418 | Al-Ali et al. | Sep 2008 | A1 |
20090036759 | Ault et al. | Feb 2009 | A1 |
20090093687 | Telfort et al. | Apr 2009 | A1 |
20090095926 | MacNeish, III | Apr 2009 | A1 |
20090247984 | Lamego et al. | Oct 2009 | A1 |
20090275813 | Davis | Nov 2009 | A1 |
20090275844 | Al-Ali | Nov 2009 | A1 |
20100004518 | Vo et al. | Jan 2010 | A1 |
20100030040 | Poeze et al. | Feb 2010 | A1 |
20100099964 | O'Reilly et al. | Apr 2010 | A1 |
20100234718 | Sampath et al. | Sep 2010 | A1 |
20100270257 | Wachman et al. | Oct 2010 | A1 |
20100331639 | O'Reilly | Dec 2010 | A1 |
20110028806 | Merritt et al. | Feb 2011 | A1 |
20110028809 | Goodman | Feb 2011 | A1 |
20110040197 | Welch et al. | Feb 2011 | A1 |
20110082711 | Poeze et al. | Apr 2011 | A1 |
20110087081 | Kiani et al. | Apr 2011 | A1 |
20110118561 | Tari et al. | May 2011 | A1 |
20110125060 | Telfort et al. | May 2011 | A1 |
20110137297 | Kiani et al. | Jun 2011 | A1 |
20110172498 | Olsen et al. | Jul 2011 | A1 |
20110208015 | Welch et al. | Aug 2011 | A1 |
20110230733 | Al-Ali | Sep 2011 | A1 |
20120123231 | O'Reilly | May 2012 | A1 |
20120165629 | Merritt et al. | Jun 2012 | A1 |
20120209082 | Al-Ali | Aug 2012 | A1 |
20120209084 | Olsen et al. | Aug 2012 | A1 |
20120226117 | Lamego et al. | Sep 2012 | A1 |
20120283524 | Kiani et al. | Nov 2012 | A1 |
20130023775 | Lamego et al. | Jan 2013 | A1 |
20130041591 | Lamego | Feb 2013 | A1 |
20130060147 | Welch et al. | Mar 2013 | A1 |
20130096405 | Garfio | Apr 2013 | A1 |
20130096936 | Sampath et al. | Apr 2013 | A1 |
20130243021 | Siskavich | Sep 2013 | A1 |
20130253334 | Al-Ali et al. | Sep 2013 | A1 |
20130274571 | Diab et al. | Oct 2013 | A1 |
20130296672 | O'Neil et al. | Nov 2013 | A1 |
20130296713 | Al-Ali et al. | Nov 2013 | A1 |
20130324808 | Al-Ali et al. | Dec 2013 | A1 |
20130331660 | Al-Ali et al. | Dec 2013 | A1 |
20130345921 | Al-Ali et al. | Dec 2013 | A1 |
20140012100 | Al-Ali et al. | Jan 2014 | A1 |
20140051953 | Lamego et al. | Feb 2014 | A1 |
20140120564 | Workman et al. | May 2014 | A1 |
20140121482 | Merritt et al. | May 2014 | A1 |
20140127137 | Bellott et al. | May 2014 | A1 |
20140163344 | Al-Ali | Jun 2014 | A1 |
20140166076 | Kiani et al. | Jun 2014 | A1 |
20140171763 | Diab | Jun 2014 | A1 |
20140180038 | Kiani | Jun 2014 | A1 |
20140180154 | Sierra et al. | Jun 2014 | A1 |
20140180160 | Brown et al. | Jun 2014 | A1 |
20140187973 | Brown et al. | Jul 2014 | A1 |
20140213864 | Abdul-Hafiz et al. | Jul 2014 | A1 |
20140275835 | Lamego et al. | Sep 2014 | A1 |
20140275871 | Lamego et al. | Sep 2014 | A1 |
20140275872 | Merritt et al. | Sep 2014 | A1 |
20140288400 | Diab et al. | Sep 2014 | A1 |
20140316217 | Purdon et al. | Oct 2014 | A1 |
20140316218 | Purdon et al. | Oct 2014 | A1 |
20140316228 | Blank et al. | Oct 2014 | A1 |
20140323825 | Al-Ali et al. | Oct 2014 | A1 |
20140323897 | Brown et al. | Oct 2014 | A1 |
20140323898 | Purdon et al. | Oct 2014 | A1 |
20140330092 | Al-Ali et al. | Nov 2014 | A1 |
20140330098 | Merritt et al. | Nov 2014 | A1 |
20140357966 | Al-Ali et al. | Dec 2014 | A1 |
20150005600 | Blank et al. | Jan 2015 | A1 |
20150011907 | Purdon et al. | Jan 2015 | A1 |
20150032029 | Al-Ali et al. | Jan 2015 | A1 |
20150038859 | Dalvi et al. | Feb 2015 | A1 |
20150073241 | Lamego | Mar 2015 | A1 |
20150080754 | Purdon et al. | Mar 2015 | A1 |
20150087936 | Al-Ali et al. | Mar 2015 | A1 |
20150094546 | Al-Ali | Apr 2015 | A1 |
20150099950 | Al-Ali et al. | Apr 2015 | A1 |
20150099955 | Al-Ali et al. | Apr 2015 | A1 |
20150101844 | Al-Ali et al. | Apr 2015 | A1 |
20150106121 | Muhsin et al. | Apr 2015 | A1 |
20150112151 | Muhsin et al. | Apr 2015 | A1 |
20150165312 | Kiani | Jun 2015 | A1 |
20150196249 | Brown et al. | Jul 2015 | A1 |
20150216459 | Al-Ali et al. | Aug 2015 | A1 |
20150238722 | Al-Ali | Aug 2015 | A1 |
20150245773 | Lamego et al. | Sep 2015 | A1 |
20150245794 | Al-Ali | Sep 2015 | A1 |
20150257689 | Al-Ali et al. | Sep 2015 | A1 |
20150272514 | Kiani et al. | Oct 2015 | A1 |
20150351697 | Weber et al. | Dec 2015 | A1 |
20150359429 | Al-Ali et al. | Dec 2015 | A1 |
20150366507 | Blank et al. | Dec 2015 | A1 |
20160000362 | Diab et al. | Jan 2016 | A1 |
20160029932 | Al-Ali | Feb 2016 | A1 |
20160058347 | Reichgott et al. | Mar 2016 | A1 |
20160066824 | Al-Ali et al. | Mar 2016 | A1 |
20160081552 | Wojtczuk et al. | Mar 2016 | A1 |
20160095543 | Telfort et al. | Apr 2016 | A1 |
20160095548 | Al-Ali et al. | Apr 2016 | A1 |
20160103598 | Al-Ali et al. | Apr 2016 | A1 |
20160119210 | Koehler et al. | Apr 2016 | A1 |
20160166182 | Al-Ali et al. | Jun 2016 | A1 |
20160166183 | Poeze et al. | Jun 2016 | A1 |
20160196388 | Lamego | Jul 2016 | A1 |
20160197436 | Barker et al. | Jul 2016 | A1 |
20160213281 | Eckerbom et al. | Jul 2016 | A1 |
20160228043 | O'Neil et al. | Aug 2016 | A1 |
20160233632 | Scruggs et al. | Aug 2016 | A1 |
20160234944 | Schmidt et al. | Aug 2016 | A1 |
20160270735 | Diab et al. | Sep 2016 | A1 |
20160283665 | Sampath et al. | Sep 2016 | A1 |
20160287090 | Al-Ali et al. | Oct 2016 | A1 |
20160287786 | Kiani | Oct 2016 | A1 |
20160296169 | McHale et al. | Oct 2016 | A1 |
20160310052 | Al-Ali et al. | Oct 2016 | A1 |
20160314260 | Kiani | Oct 2016 | A1 |
20160324488 | Olsen | Nov 2016 | A1 |
20160327984 | Al-Ali et al. | Nov 2016 | A1 |
20160331332 | Al-Ali | Nov 2016 | A1 |
20160367173 | Dalvi et al. | Dec 2016 | A1 |
20170000394 | Al-Ali et al. | Jan 2017 | A1 |
20170007134 | Al-Ali et al. | Jan 2017 | A1 |
20170007198 | Al-Ali et al. | Jan 2017 | A1 |
20170014083 | Diab et al. | Jan 2017 | A1 |
20170014084 | Al-Ali et al. | Jan 2017 | A1 |
20170024748 | Haider | Jan 2017 | A1 |
20170042488 | Muhsin | Feb 2017 | A1 |
20170055851 | Al-Ali | Mar 2017 | A1 |
20170055882 | Al-Ali et al. | Mar 2017 | A1 |
20170055887 | Al-Ali | Mar 2017 | A1 |
20170055896 | Al-Ali | Mar 2017 | A1 |
20170079594 | Telfort et al. | Mar 2017 | A1 |
20170086723 | Al-Ali et al. | Mar 2017 | A1 |
20170143281 | Olsen | May 2017 | A1 |
20170147774 | Kiani | May 2017 | A1 |
20170156620 | Al-Ali et al. | Jun 2017 | A1 |
20170173632 | Al-Ali | Jun 2017 | A1 |
20170187146 | Kiani et al. | Jun 2017 | A1 |
20170188919 | Al-Ali et al. | Jul 2017 | A1 |
20170196464 | Jansen et al. | Jul 2017 | A1 |
20170196470 | Lamego et al. | Jul 2017 | A1 |
20170224262 | Al-Ali | Aug 2017 | A1 |
20170228516 | Sampath et al. | Aug 2017 | A1 |
20170245790 | Al-Ali et al. | Aug 2017 | A1 |
20170251974 | Shreim et al. | Sep 2017 | A1 |
20170251975 | Shreim et al. | Sep 2017 | A1 |
20170258403 | Abdul-Hafiz et al. | Sep 2017 | A1 |
20170311851 | Schurman et al. | Nov 2017 | A1 |
20170311891 | Kiani et al. | Nov 2017 | A1 |
20170325728 | Al-Ali et al. | Nov 2017 | A1 |
20170332976 | Al-Ali | Nov 2017 | A1 |
20170340293 | Al-Ali et al. | Nov 2017 | A1 |
20170360310 | Kiani | Dec 2017 | A1 |
20170367632 | Al-Ali et al. | Dec 2017 | A1 |
20180008146 | Al-Ali et al. | Jan 2018 | A1 |
20180013562 | Haider et al. | Jan 2018 | A1 |
20180014752 | Al-Ali et al. | Jan 2018 | A1 |
20180028124 | Al-Ali et al. | Feb 2018 | A1 |
20180055385 | Al-Ali | Mar 2018 | A1 |
20180055390 | Kiani et al. | Mar 2018 | A1 |
20180055430 | Diab et al. | Mar 2018 | A1 |
20180064381 | Shakespeare et al. | Mar 2018 | A1 |
20180069776 | Lamego et al. | Mar 2018 | A1 |
20180070867 | Smith et al. | Mar 2018 | A1 |
20180082767 | Al-Ali et al. | Mar 2018 | A1 |
20180085068 | Telfort | Mar 2018 | A1 |
20180087937 | Al-Ali et al. | Mar 2018 | A1 |
20180103874 | Lee et al. | Apr 2018 | A1 |
20180103905 | Kiani | Apr 2018 | A1 |
20180110478 | Al-Ali | Apr 2018 | A1 |
20180116575 | Perea et al. | May 2018 | A1 |
20180125368 | Lamego et al. | May 2018 | A1 |
20180125430 | Al-Ali et al. | May 2018 | A1 |
20180125445 | Telfort et al. | May 2018 | A1 |
20180130325 | Kiani et al. | May 2018 | A1 |
20180132769 | Weber et al. | May 2018 | A1 |
20180132770 | Lamego | May 2018 | A1 |
20180146901 | Al-Ali et al. | May 2018 | A1 |
20180146902 | Kiani et al. | May 2018 | A1 |
20180153442 | Eckerbom et al. | Jun 2018 | A1 |
20180153446 | Kiani | Jun 2018 | A1 |
20180153447 | Al-Ali et al. | Jun 2018 | A1 |
20180153448 | Weber et al. | Jun 2018 | A1 |
20180161499 | Al-Ali et al. | Jun 2018 | A1 |
20180168491 | Al-Ali et al. | Jun 2018 | A1 |
20180174679 | Sampath et al. | Jun 2018 | A1 |
20180174680 | Sampath et al. | Jun 2018 | A1 |
20180182484 | Sampath et al. | Jun 2018 | A1 |
20180184917 | Kiani | Jul 2018 | A1 |
20180192924 | Al-Ali | Jul 2018 | A1 |
20180192953 | Shreim et al. | Jul 2018 | A1 |
20180192955 | Al-Ali et al. | Jul 2018 | A1 |
20180199871 | Pauley et al. | Jul 2018 | A1 |
20180206795 | Al-Ali | Jul 2018 | A1 |
20180206815 | Telfort | Jul 2018 | A1 |
20180213583 | Al-Ali | Jul 2018 | A1 |
20180214031 | Kiani et al. | Aug 2018 | A1 |
20180214090 | Al-Ali et al. | Aug 2018 | A1 |
20180218792 | Muhsin et al. | Aug 2018 | A1 |
20180225960 | Al-Ali et al. | Aug 2018 | A1 |
20180238718 | Dalvi | Aug 2018 | A1 |
20180242853 | Al-Ali | Aug 2018 | A1 |
20180242921 | Muhsin et al. | Aug 2018 | A1 |
20180242923 | Al-Ali et al. | Aug 2018 | A1 |
20180242924 | Barker et al. | Aug 2018 | A1 |
20180242926 | Muhsin et al. | Aug 2018 | A1 |
20180247353 | Al-Ali et al. | Aug 2018 | A1 |
20180247712 | Muhsin et al. | Aug 2018 | A1 |
20180249933 | Schurman et al. | Sep 2018 | A1 |
20180253947 | Muhsin et al. | Sep 2018 | A1 |
20180256087 | Al-Ali et al. | Sep 2018 | A1 |
20180256113 | Weber et al. | Sep 2018 | A1 |
20180285094 | Housel et al. | Oct 2018 | A1 |
20180289325 | Poeze et al. | Oct 2018 | A1 |
20180289337 | Al-Ali et al. | Oct 2018 | A1 |
20180296161 | Shreim et al. | Oct 2018 | A1 |
20180300919 | Muhsin et al. | Oct 2018 | A1 |
20180310822 | Indorf et al. | Nov 2018 | A1 |
20180310823 | Al-Ali et al. | Nov 2018 | A1 |
20180317826 | Muhsin et al. | Nov 2018 | A1 |
20180317841 | Novak, Jr. | Nov 2018 | A1 |
20180333055 | Lamego et al. | Nov 2018 | A1 |
20180333087 | Al-Ali | Nov 2018 | A1 |
20190000317 | Muhsin et al. | Jan 2019 | A1 |
20190000362 | Kiani et al. | Jan 2019 | A1 |
20190015023 | Monfre | Jan 2019 | A1 |
20190021638 | Al-Ali et al. | Jan 2019 | A1 |
20190029574 | Schurman et al. | Jan 2019 | A1 |
20190029578 | Al-Ali et al. | Jan 2019 | A1 |
20190038143 | Al-Ali | Feb 2019 | A1 |
20190058280 | Al-Ali et al. | Feb 2019 | A1 |
20190058281 | Al-Ali et al. | Feb 2019 | A1 |
20190069813 | Al-Ali | Mar 2019 | A1 |
20190069814 | Al-Ali | Mar 2019 | A1 |
20190117070 | Muhsin et al. | Apr 2019 | A1 |
20190200941 | Chandran et al. | Jul 2019 | A1 |
20190239787 | Pauley et al. | Aug 2019 | A1 |
20190320906 | Olsen | Oct 2019 | A1 |
20190374139 | Kiani et al. | Dec 2019 | A1 |
20190374173 | Kiani et al. | Dec 2019 | A1 |
20190374713 | Kiani et al. | Dec 2019 | A1 |
20200060869 | Telfort et al. | Feb 2020 | A1 |
20200111552 | Ahmed | Apr 2020 | A1 |
20200113435 | Muhsin | Apr 2020 | A1 |
20200113488 | Al-Ali et al. | Apr 2020 | A1 |
20200113496 | Scruggs et al. | Apr 2020 | A1 |
20200113497 | Triman et al. | Apr 2020 | A1 |
20200113520 | Abdul-Hafiz et al. | Apr 2020 | A1 |
20200138288 | Al-Ali et al. | May 2020 | A1 |
20200138368 | Kiani et al. | May 2020 | A1 |
20200163597 | Dalvi et al. | May 2020 | A1 |
20200196877 | Vo et al. | Jun 2020 | A1 |
20200253474 | Muhsin et al. | Aug 2020 | A1 |
20200253544 | Belur Nagaraj et al. | Aug 2020 | A1 |
20200275841 | Telfort et al. | Sep 2020 | A1 |
20200288983 | Telfort et al. | Sep 2020 | A1 |
20200321793 | Al-Ali et al. | Oct 2020 | A1 |
20200329983 | Al-Ali et al. | Oct 2020 | A1 |
20200329984 | Al-Ali et al. | Oct 2020 | A1 |
20200329993 | Al-Ali et al. | Oct 2020 | A1 |
20200330037 | Al-Ali et al. | Oct 2020 | A1 |
20210022628 | Telfort et al. | Jan 2021 | A1 |
20210104173 | Pauley et al. | Apr 2021 | A1 |
20210113121 | Diab et al. | Apr 2021 | A1 |
20210117525 | Kiani et al. | Apr 2021 | A1 |
20210118581 | Kiani et al. | Apr 2021 | A1 |
20210121582 | Krishnamani et al. | Apr 2021 | A1 |
20210161465 | Barker et al. | Jun 2021 | A1 |
20210236729 | Kiani et al. | Aug 2021 | A1 |
20210256267 | Ranasinghe et al. | Aug 2021 | A1 |
20210256835 | Ranasinghe et al. | Aug 2021 | A1 |
20210275101 | Vo et al. | Sep 2021 | A1 |
20210290060 | Ahmed | Sep 2021 | A1 |
20210290072 | Forrest | Sep 2021 | A1 |
20210290080 | Ahmed | Sep 2021 | A1 |
20210290120 | Al-Ali | Sep 2021 | A1 |
20210290177 | Novak, Jr. | Sep 2021 | A1 |
20210290184 | Ahmed | Sep 2021 | A1 |
20210296008 | Novak, Jr. | Sep 2021 | A1 |
20210330228 | Olsen et al. | Oct 2021 | A1 |
20210386382 | Olsen et al. | Dec 2021 | A1 |
20210402110 | Pauley et al. | Dec 2021 | A1 |
20220026355 | Normand et al. | Jan 2022 | A1 |
20220039707 | Sharma et al. | Feb 2022 | A1 |
20220053892 | Al-Ali et al. | Feb 2022 | A1 |
20220071562 | Kiani | Mar 2022 | A1 |
20220096603 | Kiani et al. | Mar 2022 | A1 |
20220151521 | Krishnamani et al. | May 2022 | A1 |
20220218244 | Kiani et al. | Jul 2022 | A1 |
20220287574 | Telfort et al. | Sep 2022 | A1 |
20220296161 | Al-Ali et al. | Sep 2022 | A1 |
20220361819 | Al-Ali et al. | Nov 2022 | A1 |
20220379059 | Yu et al. | Dec 2022 | A1 |
20220392610 | Kiani et al. | Dec 2022 | A1 |
20230028745 | Al-Ali | Jan 2023 | A1 |
20230038389 | Vo | Feb 2023 | A1 |
20230045647 | Vo | Feb 2023 | A1 |
20230058052 | Al-Ali | Feb 2023 | A1 |
20230058342 | Kiani | Feb 2023 | A1 |
20230069789 | Koo et al. | Mar 2023 | A1 |
20230087671 | Telfort et al. | Mar 2023 | A1 |
20230110152 | Forrest et al. | Apr 2023 | A1 |
20230111198 | Yu et al. | Apr 2023 | A1 |
20230115397 | Vo et al. | Apr 2023 | A1 |
20230116371 | Mills et al. | Apr 2023 | A1 |
Number | Date | Country |
---|---|---|
WO 2019089655 | May 2019 | WO |
Entry |
---|
IconBros, https://www.iconbros.com/icons/ib-mi-f-map, retrieved Nov. 3, 2020, Medical Item Collection, Map Icon Image, pp. 1. |
International Search Report and Written Opinion in corresponding International Patent Application No. PCT/US2018/058294, mailed Feb. 12, 2019, in 12 pages. |
Number | Date | Country | |
---|---|---|---|
20210212640 A1 | Jul 2021 | US |
Number | Date | Country | |
---|---|---|---|
62579575 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16175474 | Oct 2018 | US |
Child | 17218746 | US |